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Abstract 25 
Problem 26 
Chlamydia trachomatis genital tract infections are easily treated with antibiotics, 27 
however the majority of infections are asymptomatic and therefore untreated, 28 
highlighting the need for a vaccine. Because most infections are asymptomatic, 29 
vaccination could potentially be administered to individuals who may have an acute 30 
infection at that time. In such individuals the effect of vaccination on the existing 31 
infection is unknown; however one potential outcome could be the development of a 32 
persistent infection. In vitro chlamydial persistence has been well characterized in 33 
various strains, however there have been no reported studies in C. muridarum.  34 
Method of Study 35 
We performed ultrastructural characterization, and transcriptome analysis of selected 36 
genes. We then used the transcriptional profiles of the selected genes to examine 37 
whether intranasal immunization of mice during an active genital infection would 38 
induce persistence in the upper reproductive tract of female mice.  39 
Results and Conclusions 40 
We found that persistence developed in the oviducts of mice as a result of 41 
immunization. This is a significant finding, not only because it is the first time that C. 42 
muridarum persistence has been characterized in vitro, but also due to the fact that 43 
there is minimal characterization of in vivo persistence of any chlamydial species. 44 
This highlights the importance of the timing of vaccination in individuals. 45 
 46 
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Introduction 49 
 50 
Chlamydia trachomatis infections of the genital tract are mostly asymptomatic and 51 
the number of recurrent infections is increasing 1. Once an infection is established in 52 
the epithelium of the reproductive tract it is able to enter a dormant, persistent state, 53 
where it successfully avoids the host immune response and reactivates when 54 
conditions are favourable 2. If a vaccine against Chlamydia is to be successfully 55 
developed and administered to the population, including individuals that may already 56 
have an asymptomatic or chronic infection, the direct effects of the vaccine on the 57 
existing Chlamydia infection need to be examined.  58 
 59 
There have been numerous reports supporting that Chlamydia can enter a dormant, 60 
persistent state in vitro, with studies using various cell lines, different strains of 61 
Chlamydia, and various methods to induce persistence 3. Changes in both 62 
ultrastructural morphology of the Chlamydia, and the changes in bacterial gene  63 
expression are well characterized in the C. pneumoniae 4 and C. trachomatis models 64 
5, revealing common patterns between them. These include common transcriptional 65 
responses between Chlamydia species and strains, despite the persistence 66 
induction method used, and all Chlamydiae examined to date exhibit a similar 67 
persistent ultrastucture.  68 
 69 
There is a growing amount of evidence supporting the occurrence of in vivo 70 
persistence. The strongest evidence is the ultrastructural differences in inclusions 71 
observed in the cervix of mice infected with C. trachomatis 6 and C. muridarum 7, the 72 
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gastrointestinal tract of C. suis infected pigs 8 and in one human endocervical and 73 
one male urethral sample 9. Genotyping of omp1 in recurrent genital infections in 74 
women over a 2 to 4.5 year period, demonstrated identical genotypes at each 75 
recurrence 2, strongly supporting the occurrence of persistent infections. A study of 76 
women with genital chlamydial infections, who completed antibiotic treatment, found 77 
that at 1 month after completion, 10% of individuals had become re-infected, and by 78 
3 months 13% had become re-infected, even though 100% condom use or 79 
abstinence had been reported 10. There are also many reports of Chlamydia being 80 
uncultivable, but able to be detected by both PCR and ligase chain reactions (LCR) 81 
in animal models 11-13 and in human specimens 14.  82 
 83 
Immune pressure, such as interferon gamma (IFN-γ) production, is known to induce 84 
C. trachomatis into a persistent state 5, however C. muridarum, the murine variant, is 85 
not susceptible to the effects of IFN-γ 15. There is an incomplete understanding of in 86 
vivo persistence, with the majority of research examining in vitro persistence only. 87 
Genital tract chlamydial infections are largely asymptomatic, which poses the 88 
question; if vaccination is administered during an acute genital infection, could 89 
immune pressure from the immunization result in the development of a persistent 90 
infection? This is an extremely important question that needs to be addressed before 91 
any vaccine is administered to the population. 92 
 93 
In spite of C. muridarum being one of the strains more frequently used in in vivo 94 
vaccine and pathogenesis studies, there has been minimal characterization of 95 
persistent infections in this species. We therefore first sought to determine if C. 96 
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muridarum could be induced into a persistent state in vitro by culture with penicillin 97 
G. Transmission electron microscopy was used to observe morphological changes 98 
associated with persistence. The expression of 6 genes that have been used as 99 
markers of persistence in other well studied models were then examined. Once 100 
persistence was confirmed in vitro, the relative expression of the persistence gene 101 
markers were used to determine if persistent infections could be detected in vivo. 102 
Female mice were immunized intranasally during a genital infection to determine if 103 
vaccination promoted the development of in vivo persistence in the upper 104 
reproductive tract of female mice. 105 
 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
 120 
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Materials and methods 121 
 Chlamydia growth 122 
Chlamydia muridarum (ATCC VR-123, Virginia, USA), formerly the mouse 123 
pneumonitis biovar of C. trachomatis (MoPn), was grown by inoculation of McCoy 124 
cell monolayers in DMEM supplemented with 5% fetal calf serum, 2g/ml 125 
Gentamicin and 100g/ml Streptomycin sulphate, 2mM L-glutamine and 20mM 126 
HEPES. Elementary bodies were purified using a discontinuous Renografin gradient 127 
as previously described 16. 128 
  129 
Transmission electron microscopy 130 
McCoy cell monolayers in T25cm2 flasks were infected with C. muridarum at a MOI 131 
of 1. Cells were incubated at 37ºC, 5% CO2 for 4 h. Medium was then removed and 132 
replaced with supplemented DMEM + 1μg/mL cycloheximide. For flasks that were to 133 
be induced into persistent infections, supplemented DMEM + 1μg/mL cycloheximide, 134 
with 50 U/mL of penicillin G, was added. Cells were incubated for a further 12, 24, 36 135 
or 48 h under the above conditions. Medium containing penicillin G was removed 136 
from some infected cell cultures 24 h post infection and replaced with antibiotic free 137 
supplemented DMEM and cells cultured for a further 24 h. At the appropriate time 138 
points medium was removed and the cells were fixed with 3% gluteraldehyde 139 
(ProSciTech) in 0.1M cacodylate buffer (pH7.3). Cells were stored at 4ºC until 140 
processing. Cells were scraped off the flasks, washed in 0.1M cacodylate buffer and 141 
embedded in Spurr epoxy resin. Ultrathin sections (50-100nm) were cut and stained 142 
with uranyl acetate and lead citrate stains. Cells were examined and photographed 143 
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using the JEOL 1200EX transmission electron microscope (JEOL, Frenchs Forest, 144 
NSW, Australia). 145 
 146 
In vitro persistence transcript time-course 147 
Cell culture and infection 148 
McCoy cell monolayers in T25cm2 flasks were infected as above.  Medium was 149 
removed 4 h post infection and replaced with supplemented DMEM + 1μg/mL 150 
cycloheximide with or without 50U/mL penicillin G. Cells were incubated for 6, 12, 151 
18, 24 or 30 h, and at the desired time points medium was removed from infections 152 
under both conditions and 1.5mL Trizol (Invitrogen, Mulgrave, VIC, Australia) added. 153 
Flasks were left flat for 5 mins and then frozen at -80ºC until extraction of RNA. 154 
Some cultures were used for re-culturing to examine the numbers of infectious EBs 155 
present. At 36 h post infection normal and persistent cultures, and 24 h after 156 
penicillin G was replaced with antibiotic free media in reversion cultures, cells were 157 
sonicated to break down inclusions and sub-cultured onto confluent McCoy cell 158 
monolayers. Cells were incubated for a further 30 h, fixed in 100% methanol and 159 
stained with FITC anti-chlamydial LPS stain (CelLabs, Brookvale, NSW, Australia). 160 
IFUs were enumerated via visualization under a fluorescent microscope (Nikon 161 
Laborlux). 162 
 163 
RNA extraction 164 
Flasks containing Trizol (Invitrogen) were defrosted and Trizol was placed into sterile 165 
RNase/DNase free eppendorf tubes. RNA was extracted according to 166 
manufacturer’s instructions (Invitrogen). RNase/DNase free water (50μL) was added 167 
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to each sample. All samples were analyzed on the nano-drop (ND1000; Fisher 168 
Scientific, Scoresby, VIC, Australia) to confirm RNA concentration and purity. 169 
Samples were aliquoted and stored at -80ºC. 170 
 171 
In vivo persistence model 172 
Vaccination Protocol 173 
Protein production/purification: Major outer membrane protein (MOMP) 174 
The transformed Escherichia coli (DH5{pMMM3}) expressing the pMAL-c2 vector 175 
encoding recombinant MBP-MOMP fusion protein was a generous gift from Harlan 176 
Caldwell (Rocky Mountain Labs, Hamilton, MT, USA). MBP-MOMP was produced as 177 
previously described 17.  178 
 179 
Protein production/purification: Ribonucleotide reductase small chain protein sub-unit 180 
B (NrdB) 181 
Transformed E. coli (BL21 DE3) expressing the pCOLD vector (TaKaRa, Shiga, 182 
Japan) encoding recombinant His-tagged NrdB was produced and purified. Clonal E. 183 
coli colonies were grown overnight at 37ºC in 5mL LB broth containing ampicillin. 184 
This was transferred to 500ml of LB broth containing ampicillin and cultured at 37ºC 185 
and 225rpm until an OD measurement of 0.4-0.5 was obtained at 600nm. Cultures 186 
were chilled on ice for 30mins. Protein production was induced by the addition of 187 
0.5mM IPTG (Sigma-Aldrich, North Ryde, NSW, Australia), final concentration, and 188 
cultures were incubated overnight at 15°C and 225rpm. Cells were collected via 189 
centrifugation at 10,000 × g for 10 minutes at 4°C. Pellets were resuspended in 190 
50mL PBS, 0.15g Lysozyme (Sigma-Aldrich) was added and cells incubated at 37°C 191 
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for 1 hour. Bacterial protease cocktail inhibitor (Sigma-Aldrich) was added according 192 
to the manufacturer’s instructions and 1mM PMSF (Sigma-Aldrich), final 193 
concentration, was added. Cells were aliquoted to 10mL and sonicated in 15 second 194 
cycles a total of 8 times, after which time they were spun at 4,000 × g, 4°C for 10 195 
minutes. Supernatants were then spun at 10,000 × g for 10 minutes at 4°C, and 196 
supernatants frozen at -20°C until purification. 197 
 198 
Purification of NrdB was performed using the batch/gravity-flow column purification 199 
as described by the manufacturers (Talon Resin, BD Biosciences, North Ryde, 200 
NSW, Australia). Eluted protein fractions were analyzed via SDS-page. Fractions 201 
containing protein were dialyzed using cellulose dialysis membrane with an 8kDa 202 
cut-off (Sigma-Aldrich) in PBS, and then concentrated using Amplicon concentrators 203 
(Millipore, North Ryde, NSW, Australia) with a cut-off of 10kDa. 204 
 205 
Mice 206 
Female BALB/c mice, 6-8 weeks of age, were obtained from The Animal Resource 207 
Centre, Perth (Australia), and housed in an accredited laboratory animal care facility 208 
under specific-pathogen free conditions. Animals received food and water ad libitum. 209 
All procedures were approved by the Queensland University of Technology Animal 210 
Research Ethics Committee. Five animals were used in each group and each 211 
experiment was repeated twice. 212 
 213 
Genital Infection 214 
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Mice were given 2.5mg of medroxyprogesterone acetate (Depo-Provera, Pfizer, 215 
West Ryde, NSW, Australia) subcutaneously, seven days prior to infection. The mice 216 
were infected intra-vaginally with 20µl of sucrose-phosphate-glutamate (SPG) 217 
containing 5 × 104 inclusion forming units (ifu) of C. muridarum as described 218 
previously18. 219 
 220 
Intranasal Immunization 221 
Animals were immunized via the intranasal route with 5μg cholera toxin (CT; List 222 
Biological Laboratories, Campbell, CA, USA), 10μg CpG-ODN (sequence: 5’-223 
TCCATGACGTTCCTGACGTT -3’; Sigma-Aldrich), and 50μg of either MOMP alone 224 
or 50μg of MOMP and 50μg NrdB in combination. The immunization regime began 7 225 
days post infection. Animals received 3 immunizations, 1 week apart and a final 226 
boost immunization 2 weeks after the third. Animals were euthanized one week after 227 
the final immunization and reproductive tract tissues were removed, snap frozen and 228 
stored at -80ºC. 229 
 230 
Whole tissue RNA extraction 231 
A volume of 1mL of Trizol (Invitrogen) was added to reproductive tract tissue 232 
samples and tissues were homogenized. Two glass beads were added to each tube 233 
and the samples were sonicated for 2 mins in a waterbath sonicator (Unisonics, 234 
Brookvale, NSW, Australia). RNA was extracted according to manufacturer’s 235 
instructions (Invitrogen). RNA pellets were resuspended in 50µL of RNase/DNase 236 
free water and all samples were examined on the nano-drop for concentration and 237 
purity, and then stored at -80°C. 238 
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 239 
Reverse transcription 240 
Reverse transcription was performed on equal amounts of extracted RNA according 241 
to manufacturer’s instructions (Invitrogen). Briefly, 1μL of random hexamers (50ng 242 
stock), 5μg total RNA, 1μL 10mM dNTP mix (Invitrogen) and up to 13μL of sterile 243 
water were combined and heated to 65ºC for 5 mins. Samples were then placed on 244 
ice for 1 min. A master mix (reverse transcription kit obtained from Invitrogen) 245 
consisting of 4μL 5X first strand synthesis buffer, 1μL 0.1M DTT, 40U RNase OUT 246 
and 1μL superscript reverse transcriptase III per sample was prepared, and 7μL of 247 
this was added to each sample. Samples were then incubated for 5 mins at 25ºC, 248 
followed by 50ºC for 45 mins. The reaction was stopped by heating samples to 70ºC 249 
for 15 mins. Samples were stored at -20ºC. 250 
 251 
Relative gene expression 252 
Real time PCR was performed on the ABI7000 system (Applied Biosystems, 253 
Scoresby, VIC, Australia) and all primers were designed using ABI Primer Express 254 
version 2. Real time PCR reactions were performed in a final volume of 25μL, 255 
including 9µL of sterile water, 13µL of SYBR-Green (with ROX reference dye; 256 
Invitrogen), 0.5µL of 20µM forward and reverse primers (table 1; Sigma-Aldrich) and 257 
2μL cDNA. Amplification conditions consisted of 2 mins at 50ºC, followed by 10 mins 258 
at 95ºC and 40 cycles of 15 secs at 95ºC and 1 min at 59ºC. The threshold for 259 
determination of the Ct values was kept at 0.2 in subsequent runs to ensure 260 
consistency. Relative gene expression was calculated as previously described 19. A 261 
validation experiment was performed to ensure the efficiencies of the target and 262 
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reference gene were equal. As the R2 value was less than 0.1 the 2-Ct method was 263 
utilized. Briefly, the Ct values were averaged for each gene examined. For in vitro 264 
gene expression the normal infections (no antibiotics) were used as the control 265 
sample to examine the relative effect of the induction of persistence on gene 266 
expression. For in vivo samples (uterine horns and oviducts) the infection only group 267 
was used as the control sample to examine the relative effects of immunization on 268 
the state of the infection. Chlamydial 16S rRNA was used as the control gene so all 269 
expression was relative to the levels of Chlamydia present. 270 
 271 
Statistics 272 
All data presented are mean ± SD for the gene expression studies. All statistics were 273 
performed using GraphPad Prism version 5.00 (GraphPad Software, CA, USA). 274 
Significant differences in the gene expression in the in vitro studies were determined 275 
using One-way ANOVAs, with significance set for p<0.05. Significant differences in 276 
the in vivo gene expression data were determined using Unpaired Students T-test, 277 
with significance set for p<0.05. 278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
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Results 287 
We initially characterized in vitro persistence of C. muridarum in McCoy cell 288 
monolayer cultures. To do this, we determined morphological changes using TEM as 289 
well as a set of transcriptional markers as indicators of a persistent transcriptional 290 
profile. 291 
 292 
TEM analysis of penicillin-induced C. muridarum persistence. 293 
Under normal infection conditions chlamydial inclusions at 24 and 36 h post infection 294 
showed morphologically characteristic elementary bodies (EBs) (Fig. 1A and B; solid 295 
arrow head) comprising the majority of the inclusion, and only low numbers of 296 
reticulate bodies (RBs; hollow arrow). At 48 h post infection multiple inclusions were 297 
observed due to a second round of infection (Fig. 1C). The addition of 50U/mL 298 
penicillin G to cultures early in the developmental cycle caused the Chlamydia to 299 
enter a morphologically persistent form. At 20 h after addition of penicillin G (24 h 300 
post infection) there are no EBs visible and larger aberrant bodies beginning to 301 
appear (solid arrows; Fig. 1D) and the inclusion appears distinctly different to one 302 
under normal culture condition (Fig. 1A verses 1D).  By 36 h post infection large 303 
aberrant bodies (ABs; >2μm) are present, occupying the majority of space within the 304 
inclusion, with very few EBs or RBs present (Fig. 1E). The removal of penicillin G 305 
after a persistent infection was established allowed the Chlamydia to exit its 306 
dormant, persistent phase and re-enter a normal infection pattern (Fig. 1F). It can be 307 
seen that 24 h after the removal of penicillin, even though there are still ABs present, 308 
the majority of particles within the inclusion are EBs, with a few RBs also present. 309 
Sub-culture of infections further confirmed persistence with a significant decrease in 310 
 
 
14 
 
recoverable IFUs in the cultures induced into persistence, with a 1000-fold decrease 311 
in IFU (Table 2). When the penicillin was removed from cultures the number of IFU 312 
increased significantly. 313 
 314 
Expression of persistence-related genes in C. muridarum is consistent with other 315 
models of chlamydial persistence.  316 
The relative expression of genes that have been previously characterized during 317 
persistent infections in other Chlamydia species were examined via RT real-time 318 
PCR throughout the course of infection. To analyze the data the 2-∆∆Ct 19 method was 319 
used with the chlamydial 16S rRNA gene used as the control gene and the normal 320 
infection used as the control treatment at each time point. Due to penicillin 321 
preventing RB replication and halting the RB to EB conversion 20, 21 changes in gene 322 
regulation seen from 18 h post infection are due to the development of persistence. 323 
Significant changes in gene regulation prior to 18 h post infection may be due to the 324 
stage of the Chlamydia developmental cycle, rather than persistence. Because of 325 
this, differences in gene expression between control and penicillin-treated cells were 326 
only compared for significance at the 18, 24 and 30-hour time points. In this study, a 327 
greater than 4-fold change in expression was considered differential expression. 328 
 329 
Figure 2 shows the relative expression levels of the genes euo, ftsK, hctB, omcB, 330 
ompA and groEL throughout the course of persistent infection. During the course of 331 
infection euo was significantly (p<0.001) down-regulated at 24 and 30 h post 332 
infection. GroEL showed no significant change in expression throughout the course 333 
of infection. FtsK was significantly (p<0.001) down-regulated during the later stages 334 
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of infection, with a 10 fold decrease at 18 h post infection and over 100 fold decrease 335 
at 30 h post infection. HctB and omcB both had similar patterns of expression with 336 
significant (p<0.001) down regulation seen at the later stages of infection. Both 337 
genes had a greater than 10 fold decrease in gene expression at 18 and 30 h post 338 
infection and greater than 100 fold decrease at 24 h post infection. OmpA was down 339 
regulated at 6, 12 and 18 h post infection, however at 24 h post infection its 340 
expression was 3 fold greater, but by 30 h post infection it was decreased by 10 fold.  341 
 342 
This data demonstrates that C. muridarum can be induced into a dormant, persistent 343 
state in vitro and that the relative expression of persistent infection gene markers can 344 
be utilized to determine if C. muridarum infections in vivo have become persistent 345 
due to various treatments. 346 
 347 
Intranasal immunization during an active genital tract C. muridarum infection induces 348 
a persistent infection in the oviducts of mice. 349 
The relative expressions of the various genes in oviducts (Fig. 3) were examined 350 
using the 2-∆∆Ct method, where expression was relative to chlamydial 16S rRNA. The 351 
animals that received only a genital infection were used as the control treatment. The 352 
oviducts of mice immunized with a single or dual antigen vaccine were examined for 353 
the relative expression of our persistent gene markers. There was a significant 354 
difference (p<0.001) seen in the expression levels of euo, ftsK, hctB and omcB 355 
between the adjuvant only controls and the CT/CpG/MOMP and 356 
CT/CpG/MOMP/NrdB groups (Fig. 3), with the adjuvant control having up-regulated 357 
expression and the single and dual antigen groups having down-regulation, and 358 
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groEL was not detected. The uterine horns of the same mice were also examined; 359 
however the gene regulation pattern suggested there were no persistent Chlamydia 360 
present (data not shown). The level of down-regulation of the genes in the oviducts 361 
suggests that there may be persistence induced within the oviduct tissues of those 362 
animals that received the complete vaccination during an active infection.  363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
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Discussion 383 
C. trachomatis infections are often asymptomatic and can cause a range of 384 
reproductive tract problems such as PID, ectopic pregnancy and infertility 22. It has 385 
been suggested that the cause of these problems is linked to the ability of Chlamydia 386 
to enter a dormant, persistent state, where it evades host immune responses that 387 
would otherwise enhance protective immunity, but also stimulates an immune 388 
response at very low levels, causing the pathology 3, 23. C. muridarum is widely used 389 
in the mouse model to examine the efficacy of immunization regimes, but there has 390 
been minimal characterization of this species in terms of persistence. In our current 391 
study, C. muridarum persistence has been characterized in vitro, via ultrastructural 392 
analysis and examination of persistence-associated gene profiles. We also report the 393 
first evidence of in vivo persistence in murine female reproductive tract tissues using 394 
transcriptional profiles. The in vitro gene regulation data was used as a basis to 395 
examine the effects of vaccination on the bacterium. We found that those mice that 396 
received the complete vaccine formulation intranasally, during an active genital 397 
infection, developed persistent infections in the oviducts. 398 
 399 
One definition of persistence is the development of large aberrant bodies, the lack of 400 
recoverable infectious particles and the ability to revert back to a normal infection 401 
once the persistence-inducing agent is removed 23. The use of penicillin G to induce 402 
in vitro persistence in this study caused the development of characteristic aberrant 403 
bodies within the inclusions, and also a significant reduction in the number of 404 
recoverable inclusion forming units (IFU; Table 2). Ultrastructurally, normal 405 
chlamydial inclusions contain both EBs, which are approximately 0.3μm in diameter 406 
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24, and RBs which are generally 0.5-1μm 25. However, when stressed by various 407 
means, binary fission of the RBs and the conversion from RB back to EB is blocked 408 
and the Chlamydia particles enlarge 20. In our study, the removal of penicillin from 409 
the cultures allowed the persistent inclusions to revert back to normal infections, with 410 
the number of recoverable IFU increasing to levels similar to that of a normal 411 
infection (Table 2), a defining characteristic of persistence 20. The use of penicillin to 412 
examine ultrastructural changes has been used in other strains of Chlamydia. The 413 
findings in our study were similar to those seen by others using C. trachomatis 20, 21, 414 
26, 27 and C. psittaci 28, with the development of aberrant bodies (ABs) after the 415 
addition of penicillin and the return of inclusions with a normal appearance after its 416 
withdrawal. Recently, C. muridarum persistence was examined using amoxicillin and 417 
demonstrated the formation of aberrant bodies by 36 h post infection 7, consistent 418 
with our penicillin G model. 419 
 420 
In vitro transcriptional changes in response to stresses such as nutrient deprivation 421 
and the introduction of antibiotics or cytokines have been well documented 3. Whilst 422 
the exact changes depend not only on the method of induction of persistence, but 423 
also on the strain of Chlamydia and the cell line used, similarities have emerged. 424 
While the more biologically relevant system, such as the use of an immune factor 425 
like IFN-γ, to induce persistence in this particular model may have been the optimal 426 
choice to examine gene regulation and for comparison of an in vivo model, 427 
Chlamydia host trophism is intimately linked to the IFN-γ response. IFN-γ induces 428 
indoleamine 2,3-dioxygenase (IDO) in human cells which results in reduced 429 
tryptophan supply to the Chlamydia. C. trachomatis genital tract and ocular serovars 430 
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differ in their genome composition, particularly in whether they have tryptophan 431 
synthase genes which enable them to use indole to synthesise tryptophan and thus 432 
‘rescue’ it from IFN-γ induced persistence vivo 15. However, in mouse cells IFN-γ 433 
induces expression of p47 GTPases and not IDO. C. muridarum produces a large 434 
toxin, YopT, which appears to circumvent these host GTPases, therefore IFN-γ does 435 
not impact on the growth of the mouse strain C. muridarum in mouse cells, a feature 436 
we confirmed in our McCoy cell model system (data not shown). Intriguingly, these 437 
GTPases do specifically inhibit the growth of the human Chlamydia strains when 438 
they are grown in mouse cells 15.  These host trophic properties of the Chlamydia 439 
and the differing impacts of IFN-γ on the different host cell lines have been 440 
extensively investigated.  441 
 442 
In our present study we examined the effects of penicillin on C. muridarum specific 443 
gene regulation throughout the course of in vitro infection. Many of the genes, 444 
termed “late genes”, are down regulated during persistence, as they are involved in 445 
cell division, chromatin condensation and EB formation, including ftsK, hctB and 446 
omcB, respectively 3. In this study all 3 of these genes were significantly down 447 
regulated during the later stages of the developmental cycle, consistent with 448 
previous studies 5, 28-31. Euo has DNA binding activity and is proposed to function as 449 
a regulator of late gene expression 32, 33 and ensures silencing of late genes during 450 
persistence 5. In this study we found that euo was strongly down-regulated. 451 
However, its expression varies between chlamydial models, with some 452 
demonstrating strong up-regulation 28, 31, while others down-regulation 5, 31. OmpA 453 
encodes the major outer membrane protein (MOMP) that is involved in recognition 454 
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by the host immune response, the development of protective immunity 34, and 455 
maintaining the structural integrity of the Chlamydia EB 35. In many models of 456 
persistence the levels of ompA mRNA have been reduced 5, 31, and, as was found in 457 
this study, ompA was generally down-regulated. Due to the fact that MOMP is a 458 
major structural component of Chlamydia that is recognized by the host immune 459 
system, it is optimal that it’s expression is reduced during a persistent infection so as 460 
to not highlight the Chlamydia’s presence. We found that groEL was only slightly 461 
down regulated or was unchanged throughout the course of in vitro persistent 462 
infection, in comparison to the antibiotic free infections. This correlates with previous 463 
findings in other models, where a consistent and continued expression of cHSP-60 464 
was observed, while other genes were down-regulated 28, 36. There are many other 465 
gene profiles that are similar amongst the different models of persistence that could 466 
also serve as markers. However for the scope of this study, those genes that have 467 
been suggested as strong markers of persistence, using a variety of persistent 468 
induction methods in numerous models, were used to determine a gene profile for C. 469 
muridarum in vitro persistence. Due to the fact that the gene profiles examined in the 470 
present study correlate with what had been observed in the literature, we then 471 
utilized our findings to detect persistent infections in the upper reproductive tracts of 472 
female mice. 473 
 474 
The evidence supporting the occurrence of in vivo persistence is growing. However, 475 
this is the first study to investigate the effects of vaccination on persistence in 476 
animals that have an active genital infection. This study utilized the transcriptional 477 
characteristics of strong gene markers of in vitro persistence to examine the 478 
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presence of persistent C. muridarum infections in the upper reproductive tract of 479 
mice that were immunized intranasally against Chlamydia, during an active genital 480 
tract infection. We also examined gene profiles of animals treated with doxycycline 6 481 
days post infection and found no evidence of a persistent gene profile (data not 482 
shown). Infected animals treated the amoxicillin have shown via TEM to develop 483 
aberrant bodies within inclusions in the uterine horns, indicative of persistence 7. We 484 
did find, based on the gene transcriptional profiles, that immunization with either a 485 
single or dual antigen vaccine, during a genital infection, induced chlamydial 486 
persistence in the oviducts. 487 
 488 
In our study we found that groEL was not detected in the oviduct tissues, suggesting 489 
strong down-regulation. This was the only gene profile that was inconsistent with 490 
what we observed in the in vitro model of C. muridarum of persistence. As stated 491 
above, the method used to induce persistence can influence the gene transcriptional 492 
profile, which may help explain the difference seen here. Chronic infections are 493 
believed to be the cause of much of the sequelae associated with infections. It is 494 
thought that the continual exposure to cHSP-60 causes a delayed-type 495 
hypersensitivity reaction 37. As cHSP-60 is approximately 50% homologous to the 496 
human HSP-60, there may be antigenic mimicry occurring, triggering auto-immune 497 
responses against self-HSP-60, leading to pathology development 38. There are also 498 
correlations between the presence of cHSP-60 antibodies in patients that have been 499 
diagnosed with pelvic inflammatory disease and tubal factor infertility 39-42, 500 
strengthening the link. Interesting to note is that while the mice in our experiments 501 
had persistent infections in the oviducts, there was no enhanced pathology observed 502 
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at the time the tissues were examined 43. This however does not rule out the 503 
possibility that pathology would not occur to a greater severity over time. 504 
 505 
In this study, mRNA levels of our selected genes in those animals that received 506 
immunization during an active infection were indicative of a persistent infection in the 507 
oviducts, regardless of which antigens were administered. This is significant as the 508 
oviducts are highly susceptible to development of infection-associated pathology 509 
such as hydrosalpinx and tubal blockage, leading to infertility 44. In humans, the 510 
equivalent site is the fallopian tubes and damage to these leads to ectopic 511 
pregnancies and tubal factor infertility, and it has been suggested that these 512 
problems are linked to persistence 14. Also interesting to note is in our previous work 513 
we found that the dual antigen vaccine induced a poorer immune response in 514 
comparison to a singular antigen vaccine 43. It could be speculated that the induction 515 
of an inferior immune response could induce the development of persistent 516 
infections. In contrast to the oviducts, we did not observe transcriptional responses 517 
consistent with a persistent infection, in the uterine horns. This may be due to the 518 
fact that the local immune responses in these two areas differ, with different types 519 
and concentrations of cytokines and chemokines, and various levels of cellular 520 
infiltrates 45-49. This is a significant finding as there have been no studies to date that 521 
have examined the effects of an immunization during an infection on the state of the 522 
Chlamydia, even though this could occur in the general population, with 50-70% of 523 
infections being asymptomatic. 524 
 525 
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This is the first time, to our knowledge, that C. muridarum in vitro persistence has 526 
been characterized, using ultrastructural changes and corresponding transcriptional 527 
profiles of persistence gene markers investigated throughout the course of the 528 
developmental cycle. This is also the first study to examine transcriptional changes 529 
in vivo and detect persistence within the reproductive tract of female mice, 530 
highlighting that the timing of vaccination can alter the state of C. muridarum 531 
infections. This is a significant finding due to the increasing rates of genital tract 532 
chlamydial infections and the asymptomatic nature of infections. 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
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